EUVIMEDEUVIMED entdecken
Übersichtsarbeit

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?

Megan Metzger, Charles Hertz, John Mascarenhas

Clinical Lymphoma Myeloma and Leukemia · 2026-06 · 26 (6) · e730-e739

DOI: 10.1016/j.clml.2026.04.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-06. Verfasst von Megan Metzger und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Myeloproliferative Disorders Clinical Research Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Si…. Hauptthemen laut MEDLINE: Primary Myelofibrosis. Die Arbeit nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by progressive cytopenias, splenomegaly, and constitutional symptoms. The hallmark of MF pathophysiology is constitutive activation of JAK/STAT signaling, which, in the majority of cases, is associated with an acquired mutation in one of three driver mutations, JAK2, CALR, or MPL. Our growing understanding of the molecular biology of MPNs has resulted in regulatory approval of four JAK inhibitors (JAKi), which have demonstrated efficacy in improving symptom burden and reducing spleen size. Despite clear benefits of JAKi therapy, including evidence of improved survival, these therapeutic interventions have not established an ability to modify disease in terms of resolution of bone marrow fibrosis or molecular remissions. Therefore, recent emphasis has been on the development of novel therapies with informed targets outside of the JAK/STAT signaling pathway. Moreover, combination approaches utilizing JAK and non-JAK targeting agents underscore the potential for disease modification along with deeper and more durable clinical responses. Emerging combination strategies and their clinical development will be reviewed here, including investigations that pair JAKi therapy with BCL-2 family inhibitors, BET inhibitors, restored p53 cell death signals, telomerase inhibitors, PIM1 kinase inhibitors, and mutant CALR targeted therapies. While several combination clinical trials suggest improved spleen and symptom responses and the possibility of disease modification, toxicity profiles and optimal sequencing remain areas of active investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisHumansJanus Kinase InhibitorsSignal TransductionAnimalsCombined Modality TherapyMutation

Stichwörter der Autor:innen

CALR targeted therapiesCombination strategiesDisease modificationNovel therapiesSynergy

Substanzen

Janus Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Myeloproliferative Disorders Clinical Research Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Department of Medicine, State University of New York Downstate College of Medicine, Brooklyn, NY.
  • Division of Hematology/Oncology, Myeloproliferative Disorders Clinical Research Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: john.mascarenhas@mssm.edu.

Zitieren

APA

Metzger, M., Hertz, C., & Mascarenhas, J. (2026). SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?. Clinical Lymphoma Myeloma and Leukemia, 26(6), e730-e739. https://doi.org/10.1016/j.clml.2026.04.002

Vancouver

Metzger M, Hertz C, Mascarenhas J. SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?. Clinical Lymphoma Myeloma and Leukemia. 2026;26(6):e730-e739. doi:10.1016/j.clml.2026.04.002

BibTeX
@article{Metzger2026,
  author = {Metzger, Megan and Hertz, Charles and Mascarenhas, John},
  title = {SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {6},
  pages = {e730--e739},
  doi = {10.1016/j.clml.2026.04.002}
}
Kostenlos starten →